Alnylam Lowers 2026 TTR Guidance Despite $1B+ Quarterly Revenue, Stock Near 52-Week Low
ALNY is trading near its 52-week low of $262.21 (0.0% above the low).
Summary
Alnylam reported Q2 2026 total TTR net product revenues of $1.03 billion, up 89% year-over-year, driven by AMVUTTRA's $1.012 billion, with overall revenue rising 67% on increased demand for AMVUTTRA. However, the company lowered its full-year 2026 TTR product sales guidance, citing normalization of growth in second-line ATTR-CM volume after initial pent-up demand was satisfied. This guidance cut is the key negative surprise, especially with the stock already trading at its 52-week low of $262.21. On the pipeline front, two new Phase 2 studies were initiated—ALN-6400 for von Willebrand disease and mivelsiran for Down syndrome-associated Alzheimer's—and new HELIOS-B analyses were presented. The company also announced a collaboration for AI-based cardiac amyloidosis screening and expanded AMVUTTRA's commercial reach into Spain and China. The lowered outlook overshadows the revenue beat and pipeline progress, raising concerns about the ATTR-CM launch trajectory.
Updates
· SEC 8-K — The 8-K attaches the full Q2 earnings press release, including updated FY2026 guidance: total TTR net product revenues lowered to $4.2B–$4.5B, total net product revenues to $4.7B–$5.1B, and collaborations/royalties raised to $575M–$625M.
At the time of this announcement, ALNY was trading at $262.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $262.21 to $495.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.